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Makena®: A Drug for Reducing the Risk of Preterm Labor
Amanda Lovell, fifth-year pharmacy student from Lexington, Ky.; Kasie Hellmann, fourth-year pharmacy student from
Kalida, Ohio; Kelsey Fink, fourth-year pharmacy student from Hudson, Ohio; Jessica Beck, fifth-year pharmacy
student from Gibsonburg, Ohio; Michelle Musser, PharmD, assistant professor of pharmacy practice

This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity NlUilber (UAN): 0048-0000-13-177-HO 1-P

Objectives
After completion of this program, the reader should be able
to:
1. Recognize for which patients Makena® is indicated.
2. List risk factors for preterm labor and potential
consequences for premature infants.
3. State the side effects associated with Makena®.
4. Explain the potential role of the pharmacist in
dispensing Makena®.
Abstract
Makena®, hydroxyprogesterone caproate, is an intramuscular injection that is U.S. Food and Drug Administration (FDA)
approved to reduce the risk of preterm delivery before 37
weeks of pregnancy in pregnant women with a history of
spontaneous preterm birth, who are not currently carrying
multiple children. One in nine babies born in the United
States each year is born prematurely, or before 37 weeks
gestation, and mothers who have previously delivered a premature baby are 2.5 times more likely to deliver another
baby prematurely. Makena® is administered by a health care
professional as a single intramuscular injection to the hip
and has a strict window for safe administration. Hydroxyprogesterone caproate has been available as a compounded
product for years since the removal of Delalutin® from the
market in 2000. The price of Makena® has been a controversial subject since its introduction into the market due to the
increase in cost as compared to the compounded injections
that have been available in the past.
Introduction
A synthetic progestin, 17-alpha-hydroxyprogesterone
caproate, (17-0HPC, Makena®) is an intramuscular injection
that was approved by the FDA on Feb. 4, 2011, to reduce the
risk of preterm delivery before 37 weeks of pregnancy in
pregnant women with a history of at least one spontaneous
preterm birth, who are not currently carrying multiple children.1 Makena® was accepted under accelerated approval
regulations that allow drugs to be approved based on a surrogate endpoint. For Makena®, this endpoint was the reduction of risk of delivery before 37 weeks of pregnancy. The
approval committee determined that the reduced risk of de-
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livery before 37 weeks gestation observed with Makena®
treatment was reasonably likely to predict a clinical benefit
to mothers at risk for preterm delivery.1
Preterm Labor
One in nine babies born in the United States each year is born
prematurely, or before 37 weeks gestation. 2 Mothers who
have previously delivered a premature baby are 2.5 times
more likely to deliver another baby prematurely, compared
to mothers who have delivered full term.3 Prevalence of premature births is greater in women who are African American, less than 17 years old but older than 35 years old, and
those women with low income.2
There are many risk factors for preterm labor, ranging from
the physical anatomy of the uterus and cervix to certain lifestyle factors and disease states.2 Women who have previously had a preterm labor, women who are pregnant within
six months of a previous pregnancy, women who are pregnant with more than one baby, women who underwent in
vitro fertilization, and women who have certain uterus and/
or cervical abnormalities are all at an increased risk of preterm labor. Lifestyle factors such as smoking, alcohol and
drug use, standing for long periods of time, long working
hours, and exposure to chemicals and pollutants can increase
the risk of premature delivery. Additionally, stress, injuries/
accidents, violence/abuse and lack of social support can lead
to a greater risk. Certain disease states can also put a woman
at higher risk for preterm labor including diabetes, high
blood pressure or preeclampsia, obesity or underweight and
infections (sexually transmitted infections, urinary infections, vaginal infections, placental infections). Birth defects
present in the unborn baby can also put the mother at increased risk for premature delivery.
Premature infants may experience several complications
involving multiple organs and organ systems. 4 Occurrence of
complications often depends on how early the infant is born.
The respiratory system matures by week 36, but this can
often vary depending on the infant's individual development.
Infants born before 36 weeks gestation are at an increased
risk of having immature lungs, which can lead to a variety of
consequences. One potential risk is the development of respiratory distress syndrome (RDS), where the infant's immature
lungs do not produce enough surfactant, which normally prevents the lungs from collapsing. Transient tachypnea can also
occur, causing the infant to have shallow and rapid breathing. In addition to tachypnea, infants may also experience
apnea, or the absence of breathing, and bradycardia, or a
slowed heart rate. Infection and pneumonia are also a risk
due to a reduced ability to fight infections as well as possible
immature lungs.
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Other consequences of prematurity include jaundice, or yellowing of the skin due to the buildup ofbilirubin in the blood,
and anemia due to abnormally low levels of red blood cells. 4
Due to their small size and low body fat, premature infants
may also be unable to maintain their own body temperature.
The heart can be affected by a condition known as patent
ductus arteriosus (PDA) in which a specialized blood vessel
in the fetal heart, the ductus arteriosus, does not close. Patent ductus arteriosus can lead to respiratory problems and
may ultimately cause heart failure if left untreated. The infant's gastrointestinal system is also at risk for complications.
Infants born early may not have a fully developed gastrointestinal tract, which can lead to the inability of the infant to
absorb nutrients properly and effectively. Parts of the gastrointestinal tract may also receive inadequate blood flow,
which can lead to bowel wall infection and cause a serious
and potentially life threatening condition known as necrotizing enterocolitis. If born before 34 weeks of gestation, the
newborn may experience additional complications such as
intraventricular hemorrhage (IVH) and retinopathy of prematurity (ROP). Intraventricular hemorrhage is a condition
that leads to bleeding in the brain due to immature blood
vessels that are unable to handle the strain of labor and birth,
which can lead to mental retardation, learning disabilities
and cerebral palsy. Retinopathy of prematurity can potentially cause blindness in the newborn.2.4
Management of Prete rm Labor
Women experiencing premature labor are often put on bed
rest to decrease physical activity and are advised to increase
fluid intake. Doctors may also tell women to refrain from the
use of tampons and douches and to avoid having sex. If the
cervix starts to open too early, a procedure known as a cerclage is performed. During a cerclage, a stitch is put in the
cervix and left in place until the mother is 37 weeks pregnant.2
Pharmacologic treatment of preterm labor often involves the
use of progesterone and tocolytics.s Tocolytics include drugs
such as magnesium sulfate, indomethacin, nifedipine and
terbutaline, and may also be used to slow contractions during preterm labor. Health care providers may give tocolytics
after 17 to 20 weeks gestation and prior to 34 weeks gestation. The specific medication used as well as duration of therapy depend on time in pregnancy, the status of the fetus and
the overall risk of actual preterm labor. Tocolytics can delay
labor for approximately 48 hours, but for some women labor
may be delayed several days.
Progesterone is used, either as a vaginal gel or as an injection, to relax the uterus and prevent contractions.6 Progesterone injections may be used weekly starting at 16 weeks,
while the gel can be started around 20 weeks and is applied
daily. The gel or injection may be used until 37 weeks gestation. To qualify for the use of the injections, a woman must be
pregnant with only one baby or have previously experienced
preterm labor with a single baby.
Makena®
Makena® is a synthetic progestin that has effects similar to
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progesterone. Progesterone is needed for implantation of a
fertilized egg into the uterus and is also responsible for maintaining pregnancy. The mechanism in which progesterone
accomplishes this is unknown, but is hypothesized to help
relax the muscles of the uterus and reduce the rate of cervical shortening. 7•8 The synthetic progestin appears to have
differing effects on the muscles of the uterus and has either
produced no change or increase in uterine contraction.9 A
review by O'Brien9 analyzed several studies primarily to determine the safety of progesterone and 17-0HPC. The author
makes a distinction that natural progesterone is handled differently in the body from the synthetic and, therefore, may
have different safety profiles. The author also reviews differences in the efficacy and safety when comparing women with
singleton pregnancies to those with multiple pregnancies.
The studies have shown that in patients with multiple
fetuses, 17-0HPC can reverse the intended agonism on the
progesterone receptor and create an antagonistic effect. Progesterone receptor antagonism is based on the patient's
genotype and the number of fetuses per pregnancy. It may
also lead to a miscarriage or impaired fetal growth in some
populations. Studies have shown that the progesterone receptor gene is located on chromosome 1 lq. Polymorphisms
in this gene may result in adverse events in pregnancy such
as preterm labor. Manuck et aJ.10 examined the progesterone
receptor polymorphisms in women with previous spontaneous preterm births and the clinical response to 17-0HPC.
This was an exploratory study conducted as a secondary review of patients from a previous study 11 so the results must
be considered with caution. The authors noted several polymorphisms associated with a greater risk of spontaneous
preterm births, as well as differences in response to 17-0HPC
depending on genotype.10 Therefore, based on the patient's
progesterone receptor, treatment with 17-0HPC may trigger
preterm labor; however, at this time genetic testing is not
required or suggested prior to starting Makena® therapy.
The approval of Makena® did not mark the first instance of
FDA approval of hydroxyprogesterone caproate. In 1956,
Delalutin® was approved by the FDA for indications that included the threat of miscarriage.1.12 This was prior to the
FDA Drug Amendment Act of 1962 which required that
efficacy be shown in a controlled clinical trial for market
approval. In 2000, the FDA removed Delalutin® from the
market at the request of the manufacturer (who was no
longer producing the drug); this withdrawal was unrelated
to safety.1.12 A compounded form of injectable hydroxyprogesterone caproate has been used off-label for many years.
The approval of Makena® was made on a single controlled
clinical trial with the expectation that the manufacturer
would provide additional data. The study conducted was a
multicenter, randomized, double-blind clinical trial that enrolled 463 women who were pregnant with a single fetus and
had a history of preterm birth. In the placebo control group
of the study, 55 percent of patients delivered before week 37
as compared to 37 percent delivered before week 37 in the
group treated with 17-0HPC.Ul There was also a significant
decrease in preterm deliveries at weeks 35 and 32 as compared to the placebo group, although this was not as strong
statistically. The authors calculated the number-needed-to-
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treat (NNT) to prevent one preterm delivery before 37 weeks
in patients with similar risk to those in this study was between five and six (95 percent confidence interval, 3.6 to
11.1).11 In order to prevent one preterm delivery before 32
weeks, the NNT was calculated to be 12 (95 percent confidence interval, 6.3 to 74.6). Given that the greatest risk to
the neonate is when delivery is prior to 32 weeks, the use of
37 weeks as the surrogate endpoint may not be as telling. 12
The authors did review outcomes in the infants and found in
patients who received 17-0HPC versus placebo a significant
decrease: in infants weighing less than 2500 gm at birth; in
rates of necrotizing enterocolitis; in IVH of any grade; and
need for supplemental oxygen.11 There was a decrease
(nonsignificant) in: infants weighing less than 1500 gm at
birth; neonatal death; transient tachypnea; respiratory distress syndrome; bronchopulmonary dysplasia; ventilator
support; patent ductus arteriosus; and retinopathy. Of concern was a nonsignificant increase in fetal death in the 17 OHPC treated group. Further trials are needed to evaluate
this and more long term effects on the children born to mothers treated with 17-0HPC.
Makena® is administered by a health care professional as a
single intramuscular injection to the hip.3 Women may receive 250 mg of Makena® via intramuscular injection once
weekly starting between 16 weeks and zero days, and 20
weeks and six days of gestation. The weekly doses of
Makena® continue until week 37 of gestation or delivery of
the baby.
The most common side effects of Makena® are pain, pruritis,
and/or swelling at the injection site, as well as some gastrointestinal upset such as nausea and diarrhea. 13 Some women
may experience urticaria, or hives, in the area of injection. A
more serious side effect that is often a risk when taking hormone replacement therapy is a thromboembolic disorder.
This can become a life threatening event and the patient
should receive medical attention if a thromboembolic disorder develops. 4 Women should not use Makena® if they have a
history of thromboembolic events, have hormone sensitive
cancer, unusual vaginal bleeding, active liver disease or uncontrolled hypertension.13 Makena® is not shown at this time
to have negative impacts on the infants later in life. Further
safety studies are continuing to detect these potential outcomes. Hydroxyprogesterone caproate is a CYP3A substrate
and a strong CYP2A6 inhibitor. Drug interactions can be expected with other drugs that affect these enzyme systems. 14

KV pharmaceuticals decreased the cost of the drug to $690
per injection.16 Even with this reduction in price, the cost of
use of Makena® may still exceed the savings in overall health
care costs due to less preterm births. Based on a conservative NNT of 14, 139,000 at-risk women would need to be
treated to prevent 10,000 premature births.17The total direct
and indirect medical costs for 10,000 premature births is
estimated at $519 million. Even at the new, reduced price of
$690 per injection of Makena®, the cost of treatment of
139,000 women with Makena® for 20 weeks would exceed
$1.9 billion. In comparison, the cost of the compounded form
of 17-0HPC to treat 139,000 women would be approximately
$41,700,000-considerably less than the medical costs associated with 10,000 premature births.
To help assist patients with the costs of Makena®, KV pharmaceuticals developed a patient assistance program. The
financial aid is based on the patient's insurance status, as
well as their household income. This financial assistance may
make Makena® an option for those who need it but cannot
afford it.lB Table 1 displays the financial assistance available
based on a family's income and insurance for Makena®.
Conclusion
Makena®, though not the first drug of its kind, has been FDA
approved for the treatment of preterm labor in patients at
risk This medication has gained recent media attention due
to the FDA decision to not enforce the exclusivity of KV Pharmaceutical to market the drug, which has significantly increased patient awareness of this drug and its benefits in
preventing preterm delivery. As pharmacists, it is important
to understand how Makena® works and which patients qualify for administration in order to refer patients to their gynecologist for further treatment. Though this product is very
expensive, pharmacists are available to give information
about the compounded hydroxyprogesterone caproate injection that may be available in their area, as well as information on financial assistance for Makena®. The accessibility of
pharmacists within the community allows for an increased
availability to patients and physicians with questions about
preterm labor and the benefits that treatment options, such
as Makena®, may provide.

Controversy has surrounded this drug and its manufacturer,
KV Pharmaceuticals, since its approval. The compounded
form of hydroxyprogesterone caproate was available for
around $15 per injection. When Makena® came on the market, the cost was $1,500 per injection.is When the FDA made
its original approval as an orphan drug, KV Pharmaceuticals
was allowed exclusive rights to the product for seven years.
The FDA, however, decided not to enforce the exclusivity of
KV pharmaceuticals and allowed pharmacists to continue to
compound hydroxyprogesterone caproate at a lower price.
This led to a large drop in stock of Makena ® and eventually
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Table 1. Assistance Provided by the Patient Assistance Program for Makena ®.10
Coverage

Income Level

Copay/Financial Assistance*

Uninsured

Up to $60,000

Receive Makena® at no cost

Uninsured

Above $60,000

Receive Makena® at cost equivalent to what
insured patients pay out-of-pocket under the Makena®
copay assistance program

Insured

Up to $120,000 (represents 85 percent of
household incomes based on 2009 census data)

Copay of $0-$20 per injection for Makena®

Insured

Above $120,000 (represents 15 percent of
household incomes based on 2009 census data)

Copay of$40-$80 per injection for Makena®

*This encompasses 85% of U.S. household incomes. Source: 2009 U.S. Census Data.
*Gross annual household income and insurance coverage are factors that determine the level of copay or financial assistance for which a
patient is eligible. There are additional eligibility requirements (i.e. have a Makena® prescription, etc.) and these can be discussed on patientby-patient basis with a representative from the Makena® Care Connection, a program designed to help ensure access to Makena®.
http://www.kvph.com/Makena/cost-ofbringing-makena-to-marketaspx; reprinted with permission: Medical Information, Ther Rx, division of
KV Pharmaceuticals. Accessed May 23, 2013.
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Assessment Questions

1.

Makena® is indicated for:
A. Women with no prior history of preterm birth
8. Women carrying multiple children
C. Women with a singleton pregnancy
D. Women that are greater than 37 weeks gestation

2.

Makena® is a(n):
A. Self-administered intramuscular injection
8. Tablet
C. Intravenous drip
D. Intramuscular injection administered by a
health care professional

3.

4.

Hydroxyprogesterone caproate was previously FDA
approved under the name:
A. Delalutin®
8. Endometrin®
C. Mirena®
D. Prometrium®
Women who have previously delivered a premature
baby are how many more times likely to deliver
prematurely again?
A. 5
B. 3.5

c.

D.

5.

6.

7.
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8.

Some common side effects a patient receiving Makena®
may experience include all of the following EXCEPT:
A. Pain and swelling at the injection site
B. Hives in the area of the injection
C. Headache
D. Nausea and vomiting

9.

Which serious side effect is life-threatening in which the
patient should seek medical attention immediately?
A. Respiratory distress syndrome
B. Seizures
C. Depression
D. Thromboembolic disorder

10. What is/are the best way(s) a pharmacists can assist a
patient that may be a candidate for Makena®:
A. Explaining the benefits Makena® can have on a
preterm pregnancy
B. Provide information about financial assistance
to help pay for Makena®
C. Understand which patients qualify for Makena®
and refer the patient to her gynecologist
D. All of the above are ways a pharmacists can
assist a patient

2.5
3

Other treatment options for premature labor include:
A. Tocolytics
B. Progesterone
C. Cerclage
D. Aand B
E. All of the above
All of the following increase incidence of premature birth
EXCEPT:
A. Asian descent
8. Age <17 and >35
C. Low income
D. In vitro fertilization
Potential risks for the premature baby include:
A. Respiratory distress syndrome
B. Jaundice
C. Intraventricular hemorrhage
D. All of the above are potential risks of premature
delivery

To receive continuing education credit for this program, you
must answer the above questions and fill out the evaluation
form. Please visit www.onu.edu/pharmacy to enter the
required information. Please allow two to three weeks for
electronic distribution of your continuing education certificate, which will be sent to your valid email address in PDF
format.
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To receive continuing education credit for this program, visit www.onu.edu/pharmacy/CE OR fill out the form below
including your indicated answers to the assessment questions and return to:
Office of Continuing Education at the Raabe College of Pharmacy
Ohio Northern University
525 South Main Street
Ada, Ohio 45810

Program Title: Makena®: A Drug for Reducing the Risk of Preterm Labor
UAN: 0048-0000-13-177-H01-P CEUs: 0.1
All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of
continuing education credit. Certificates will be distributed as a PDF document to a valid email address.
Name:
Address:
City:

State:

Phone:

Email:

Pharmacy License #:

State:

Zip:
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ONU Alumni?

The program objectives were clear.

N

1

2

3

4

5

Recognize for which patients Makena® is indicated.

1

2

3

4

5

List risk factors for preterm labor and potential consequences for
premature infants.

1

2

3

4

5

State the side effects associated with Makena®.

1

2

3

4

5

Explain the potential role of the pharmacist in dispensing Makena®.

1

2

3

4

5

The program met your educational needs.

1

2

3

4

5

Content of the program was interesting.

1

2

3

4

5

Material presented was relevant to my practice.

1

2

3

4

5

The program met the stated goals and objectives:

Comments/Suggestions for future programs:

Thank you!
Answers to Assessment Questions-Please Circle Your Answer

1.ABCD

4.

A B C D

2.

A B C D

5.

A B C D

3.

A B C D

6.

A B C D

E

Any questions/comments regarding this continuing education program can
be directed to Lauren Hamman, Advanced Administrative Assistant for the
Office of Continuing Education (email : l-hamman@onu.edu, phone 419772-2280).

7.

A B C D

8.

A B C D

9.

A B C D

10. A B C D

Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 05116/16.

